I recently saw a patient who had been through four pain specialists, two psychiatrists, and a medication list that read like a pharmacy inventory. She was fifty-three, dealing with chronic widespread pain that had gradually taken her career, her sleep, and most of her social life. Her imaging was clean. Her labs were unremarkable. She had tried gabapentin, duloxetine, and two rounds of cognitive behavioral therapy. Nothing moved the needle. What nobody had done was look at how her brainstem was processing pain signals, or whether her vagus nerve was part of the problem.
A study published in June 2026 in Nature Neuroscience helps explain why cases like hers get stuck, and it points toward something we can actually do about it.
The Pathway Nobody Had Mapped
For decades, clinicians have known that vagus nerve stimulation can reduce pain. The FDA approved implanted VNS devices for epilepsy in 1997 and treatment-resistant depression in 2005, and physicians observed pain relief as a consistent side effect. The problem was that nobody could explain the mechanism with any precision. We knew it worked. We did not know how.
The Fudan University team, led by Deng Hanfei at the Institute of Brain Science, changed that. Working in a mouse model, they identified a specific set of neurons in the caudal nucleus of the solitary tract that project directly to the periaqueductal gray. That pathway, cNTS to PAG, is the route through which vagus nerve stimulation suppresses both the sensory experience of pain and the negative emotional states that accompany it.
The periaqueductal gray is not a new structure to pain researchers. It has been implicated in descending pain modulation for years. What is new is the direct anatomical connection from the vagal relay station in the brainstem to this region, and the demonstration that activating those specific neurons reproduces the analgesic and mood effects of VNS. When the researchers used optogenetics to activate cNTS-PAG neurons, the animals showed reduced pain behavior. When they silenced those neurons, VNS lost its effect. The pathway is necessary and sufficient.
The study also found that this circuit modulates dopamine signaling in the nucleus accumbens, which means VNS is not just dampening pain signals. It is altering the reward and motivation circuitry that determines how much suffering a painful stimulus actually produces. Pain, as any chronic pain patient will tell you, is not just a sensation. It is an emotional experience, and this pathway governs both dimensions.
Why Precision Targeting Matters Now
This finding lands differently when you consider what we can do with neuromodulation technology in 2026. Transcranial magnetic stimulation has been FDA-cleared for depression, OCD, and smoking cessation, and the evidence base for pain is growing. But the clinical results with TMS have always been variable, and one reason is targeting. A TMS coil positioned over the dorsolateral prefrontal cortex, the standard depression target, does not necessarily engage the same downstream circuits in every patient.
This is where neuronavigation changes the equation. Using a patient's own structural MRI, neuronavigation systems guide TMS coil placement to within millimeters of a specific cortical target. Instead of placing the coil at a population-average coordinate, we can target the exact region of prefrontal cortex that connects, through white matter tracts, to the periaqueductal gray and the brainstem pain modulatory system the Fudan team just mapped.
The clinical implication is straightforward. If we know that VNS works through cNTS-PAG neurons, and we know that TMS can modulate PAG activity through cortical-subcortical connections, then the combination of neuronavigated TMS and vagal nerve stimulation becomes a precision intervention rather than a broad-spectrum one. We are no longer stimulating the brain and hoping the right circuits respond. We are targeting the circuits the evidence identifies.
What This Means for Chronic Pain and Anxiety
The dual nature of this pathway, suppressing both sensory pain and negative affect, is what makes it particularly relevant to the patients I see. Chronic pain rarely travels alone. It brings anxiety, disrupted sleep, cognitive fog, and a progressive withdrawal from the activities that give life meaning. Standard pain management treats each of those symptoms separately: a medication for pain, another for anxiety, another for sleep. The Fudan finding suggests that a single neural pathway may be driving the entire constellation.
In our Intensive Brain Health Program, we already combine neuromodulation with metabolic and neuroinflammatory workups because the brain does not fail in isolated compartments. A patient with chronic pain typically has measurable neuroinflammation, disrupted cortisol rhythms, and altered neurotransmitter metabolism. Treating the pain without addressing the metabolic environment is like changing the oil in a car with a cracked engine block. The Fudan pathway finding adds another layer: we can now target the specific brainstem circuit that integrates pain and emotional distress, using non-invasive tools that did not exist a decade ago.
I wrote in June about why the vagus nerve deserves more clinical attention than it gets. That post focused on the gut-brain axis and how vagal signaling affects everything from inflammation to mood. This new pathway data extends the argument. The vagus nerve is not a single-function cable running from the gut to the brain. It is a distributed system with specific, mappable circuits that govern distinct physiological and emotional responses. Mapping those circuits is what turns vagal nerve stimulation from a blunt instrument into a targeted therapy.
The Neuroeconomy Angle
For the executives and high-performers who come to NGP, chronic pain is not just a quality-of-life issue. It is a cognitive tax. Pain consumes attentional resources. It fragments working memory. It degrades the executive function that careers and businesses depend on. The research on pain-cognition interference is consistent: chronic pain patients show measurable deficits on tasks requiring sustained attention, cognitive flexibility, and decision-making under uncertainty.
If this brainstem pathway governs both the pain signal and the emotional amplification of that signal, then targeting it does not just reduce suffering. It frees up cognitive bandwidth. That is the Neuroeconomy thesis applied to pain: your brain's processing power is finite, and anything that consumes it without producing value is a cost you can choose to address.
Where We Go From Here
The Fudan study is preclinical. The pathway was mapped in mice, and translating brainstem circuit findings to human therapeutics takes time and careful work. But the anatomy of the vagus nerve and the NTS-PAG connection is conserved across mammals, and the non-invasive tools to modulate these circuits, TMS with neuronavigation and transcutaneous vagal nerve stimulation, already exist and are already in clinical use for other indications.
What changes now is the rationale. We are no longer applying neuromodulation to pain based on empirical observation alone. We have a circuit-level explanation for why it works, and that explanation tells us exactly where to aim. For patients like the woman I described at the top of this post, that specificity is the difference between another round of trial-and-error medications and a treatment plan built on the biology of what is actually going wrong.